Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | MC4R | P32245 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6734580 | 0.92 | PTGS1 (0.57) | KMT2APTGS1LMNAHTTSMN1; SMN2 | |
| SCHEMBL6742844 | 0.89 | PTGS1 (0.62) | KMT2APTGS1LMNAHTTSMN1; SMN2 | |
| SCHEMBL6739277 | 0.87 | PTGS1 (0.59) | KMT2APTGS1LMNAHTTSMN1; SMN2 | |
| SCHEMBL6738758 | 0.86 | LMNA (0.47) | KMT2APTGS1LMNAHTTSMN1; SMN2 | |
| SCHEMBL6740507 | 0.85 | KMT2A (0.55) | KMT2APTGS1LMNAHTTSMN1; SMN2 | |
| SCHEMBL6723829 | 0.85 | PTGS1 (0.58) | KMT2APTGS1PTGS2ABCB11ALDH1A1 | |
| SCHEMBL6737927 | 0.84 | PTGS1 (0.57) | PTGS1LMNAHTTSMN1; SMN2PTGS2 | |
| SCHEMBL6739886 | 0.84 | LMNA (0.46) | KMT2APTGS1LMNAHTTSMN1; SMN2 | |
| SCHEMBL6739118 | 0.83 | CYP19A1 (0.63) | KMT2APTGS1PTGS2ABCB11ALDH1A1 | |
| SCHEMBL6739443 | 0.82 | PTGS2 (0.47) | PTGS1LMNAHTTSMN1; SMN2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686390-B2 | DIHYDROFURANONYL- OR DIHYDROPYRROLINONYL-PHENYL COMPOUNDS CONTAINING SUBSTITUTED THIO, SULFOXIDE OR SULFONYL GROUPS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2004-02-03 | — | — | US | claimed |
| US-20020032230-A1 | Novel compounds having antiinflamatory activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LTD. | 2002-03-14 | — | — | US | claimed |
| WO-2001090097-A2 | NOVEL COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-11-29 | — | — | WO | claimed |
| US-6686390-B2 | DIHYDROFURANONYL- OR DIHYDROPYRROLINONYL-PHENYL COMPOUNDS CONTAINING SUBSTITUTED THIO, SULFOXIDE OR SULFONYL GROUPS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2004-02-03 | — | — | US | disclosed |
| US-20020032230-A1 | Novel compounds having antiinflamatory activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LTD. | 2002-03-14 | — | — | US | disclosed |
| WO-2001090097-A2 | NOVEL COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032230-A1 | Novel compounds having antiinflamatory activity: process for their preparation and pharmaceutical compositions containing them | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TPSAB1, ACE | KMT2A 4740/4885PTGS1 42/4885LMNA 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.